Cagrilintide is a groundbreaking long-acting amylin analog poised to revolutionize obesity and type 2 diabetes management with its powerful, once-weekly appetite suppression and metabolic enhancement. Pending FDA review, it promises significant weight loss and improved health outcomes.
Mechanism
Cagrilintide functions as a dual agonist targeting amylin and calcitonin receptors, effectively curbing appetite and slowing gastric emptying. This leads to extended feelings of fullness and reduced calorie intake, alongside modest glucagon suppression for better glycemic control, making it a potent ally in weight loss and metabolic health.
Research
In Phase 3 trials, participants experienced an astounding average weight loss of 22.7% over 68 weeks when combining cagrilintide with semaglutide (CagriSema). Remarkably, 60% of those treated achieved over 20% weight loss, underscoring Cagrilintide's transformative potential in obesity treatment.
Synergies
Cagrilintide pairs exceptionally well with GLP-1 receptor agonists like semaglutide, amplifying appetite control for more significant weight loss success. Ben IQ customizes a strategy based on YOUR labs and goals for optimal results.
Trade-Offs
While Cagrilintide offers substantial benefits, it's essential to be aware of potential gastrointestinal side effects and specific contraindications. These general considerations should be tailored to YOUR unique health profile.